Investing in a differentiated preclinical liver disease program.
Curaem is seeking aligned investors to support clinical-readiness, production capability, controlled cultivation, regulatory planning, and future market access development.
Why Curaem, and why now.
Large unmet need
HBV and chronic liver disease remain major global health burdens.
Differentiated development angle
Standardized plant-derived investigational candidate developed through reverse pharmacology.
Preclinical-stage foundation
Early-stage validation work spans botanical, biological, and hepatoprotective research.
Standardization strategy
Controlled sourcing, marker-component tracking, and quality-focused formulation.
Capital-efficient pathway
Reverse-pharmacology development may support a more focused route from candidate to clinical readiness.
Partnership potential
Future regional access, manufacturing, and strategic pharma partnerships.
Where the next round accelerates the program.
Detailed round structure, financial model, use of proceeds, and diligence materials are available to qualified investors under NDA through appropriate legal and diligence processes.
Preview of the data room.
Request the Curaem investor deck.
Contact our investor relations team directly to receive the investor deck and discuss next steps. Materials are shared through appropriate legal and diligence processes.
This website is not an offer to sell securities. Investment information is provided only to qualified parties through appropriate legal and diligence processes.
Contact Investor Relations
Email Satia Narjadin directly to request the investor deck and begin diligence discussions under confidentiality.
Request Investor Deck